Results: Ten patients (two allogeneic, eight autologous recipients) with median age 5.4 years (range 2.7-12.2 years) were enrolled. Before Hib vaccination, 60% of patients' anti-PRP IgG titers were below 0.15 μg/mL. After vaccination, 100% of patients' anti-PRP IgG titers increased above 0.15 μg/mL (cut-off value for detection) and 1.0 μg/mL (cut-off value for seroprotection). For pneumococcus, in 2-5 year-old patients, pre-vaccination geometric mean concentrations (GMCs) of IgG for six serotypes (4, 6B, 9V, 14, 18C, and 23F) were below 0.35 μg/mL and at 5 months post-vaccination GMCs of IgG for all seven serotypes increased to above 0.35 μg/mL. In patients older than 5 years, pre-vaccination GMCs of IgG for four serotypes (4, 9V, 14, and 23F) were below 0.35 μg/mL and at 3 months post-vaccination GMCs of IgG for all seven serotypes increased to above 0.35 μg/mL. Conclusion: Most HCT recipients had low or no protective antibodies to Hib and Sp before vaccination, but showed good immune responses to protective levels after vaccination.
Introduction
Hematopoietic cell transplantation (HCT) recipients are highly immunocompromised and are susceptible to many viral and bacterial infections, including Hib and Sp. Vaccines against these pathogens are thus typically recommended in HCT recipients 1, 2) . Antibody titers to vaccine-preventable infections such as tetanus, polio, measles, mumps, and rubella decline during the 1-10 years after allogeneic or autologous HCT if the recipient is not revaccinated 3) . In these patients, infections are more frequent and/or severe than in the general population 4) . Therefore HCT recipients should be routinely revaccinated after HCT in order to develop immunity to these pathogens.
HCT recipients have qualitative and quantitative
T and B cell deficiencies and functional granulocyte deficiencies (impaired chemotaxis), which predispose them to be susceptible to serious invasive infection by encapsulated bacteria such as Hib and Sp 5, 6) .
The epidemiology of fatal infection due to Sp has been well studied in terms of both early and late post-HCT periods by the European Group for Blood and Marrow Transplantation (EBMT) survey of 3,451 HCT recipients 7) . The incidence of invasive pneumococcal disease (IPD) was 2.03/1,000 transplants in the early post-HCT period and 8.63/1,000 transplants in the late post-HCT period. In addition, it was increased in patients with chronic graft versus host disease (GVHD) to up to 18.85/1,000 transplants. Although autologous HCT recipients are less prone than allogeneic recipients to develop IPD, the incidence was still high, with an incidence of 4.6/ 1,000 transplants. The mortality rate was 20%. In a US study of 7,888 HCT recipients, the incidence of IPD was 7/1,000 transplants and the mortality rate was 13% 8) . Compared to Sp infection data, there are only handful of data regarding Hib infection in HCT recipients. Although fatal infection is less common than pnuemococcus, Hib is another encapsulated bacteria that can cause infectious complication in HCT recipients. In late 1970s, a study reported that about 7% of bacterial infection was caused by Hib infection in 89 long-term survivors after HCT. In 1980s studies, Hib was also observed as one of the pathogens responsible for pulmonary infection complications in HCT recipients 6, 9, 10) . 
Materials and Methods

Participants and Vaccination
1) Patients
Pediatric HCT recipients were prospectively enrolled and followed at Samsung Medical Center, based on their age at presentation for vaccination.
Group I included patients from 2-5 years of age 
2) Vaccination Schedule and Serum Collection
Patients in group I and group II received post-HCT vaccinations against Hib and Sp, and serum collection was performed as scheduled (Table 1) .
At the time when this study was designed and . On the other hand, the EBMT recommended only one dose of PPSV23 at 12 months after HCT 4) . At that time, there were no official guidelines for vaccination with 7-valent pneumococcal conjugate vaccine (PCV7). However, since there was increasing evidence for immunogenicity and safety of PCV7 vaccination in pediatric HCT recipients [11] [12] [13] , we chose to combine the PCV7 and PPSV23 schedule in children 2-5 years of age. In children >5 years old, we chose one dose of PPSV23
for our study protocol. IgG antibody concentration of 60.9 μg/mL. The cutoff of the ELISA for PRP detection was 0.15 μg/mL and seroprotection was defined as an antibody concentration ≥1.0 μg/mL after vaccination 13, 16) . The seroprotection response rate was analyzed. The proportion of subjects achieving levels ≥0.15 μg/mL was also calculated.
2) ELISA for IgG for Sp
Anti-pneumococcal antibodies against serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F were measured by ELISA using both C-polysaccharide (C-PS) and 22F serotype capsular polysaccharide absorption, as previously described 17, 18) . ELISA was performed at After another two-hour incubation at RT, 50 μL of 3 M NaOH was added to all wells to stop the enzyme reaction. The optical density was measured at 405 nm and the optical density at 690 nm was subtracted.
Optical densities were converted to antibody concentrations using the software for pneumococcal
ELISA provided by the CDC (written by Brian
Plikaytis at the CDC, Atlanta, GA, U.S.A). A free software download is available from www.cdc.gov/ ncidod/dbmd/bimb/elisa.htm, and a detailed protocol is available online at www.vaccine.uab.edu. Seroprotection from Sp infection was defined as an antibody concentration ≥0.35 μg/mL after vaccination 13, 19) , and the seroprotection response was analyzed.
Statistical Analyses
Immunogenicity analyses after vaccination and safety assessments were based on the modified intent-to-treat cohort, which included all vaccinated infants for whom data were available. Medians were calculated for lymphocyte subset analysis and the geometric mean concentrations of pre-vaccination IgG, IgA, IgM, IgD, and IgE levels were calculated.
For the lymphocyte proliferation assay, each patient's lymphocyte proliferation stimulation index (SI) was calculated and patients whose SI values were lower than 50% of the control were identified. 
Ethical Considerations
The study protocol was approved by the Institu- 
Results
Patient Characteristics and Immune Function before Vaccination
1) Patient Characteristics
Patients' characteristics are summarized in Table 2 .
Ten patients were enrolled, and the male to female 
2) Immune Function of Enrolled Patients before Vaccination
Immune function before vaccination was evaluated in all patients except patient 5 by determination of lymphocyte subsets, lymphocyte proliferation testing, and measurement of IgG, IgA, IgM, IgD, and IgE (Table 3 and 4, and Fig. 1) . The patients' quantitative immune functions appeared to be recovering well.
All of the patients' absolute lymphocyte counts were above 2,000/μL and their CD4 counts were above Tests for lymphocyte function were also performed in all patients except patient 5 (Fig. 1) . The SI values of patients 1, 4, 8, 9, and 10 were below were below 50% of normal control SI values when stimulated by ConA.
3) Adverse Events after Vaccination
A total number of vaccinations were 16 in group I (four patients and 4 vaccination visits per patient).
In group II, the third Hib vaccination was not performed in patient 6 and 7. Consequently, a total of sixteen vaccinations were performed in group II (six patients and 3 vaccination visits per patient). Any reported adverse events of grade III or more are shown in Table 5 . No serious adverse events were observed during the study period.
Antibody Response to Hib
Anti-PRP IgG concentrations after Hib vaccination are shown in Table 6 
Antibody response to Sp
1) Antibody Response to Sp in 2-5 year-old Children (Group I)
Antibody responses to Sp in children aged 2-5 years are summarized in Table 7 and However, we did not observe any further increases 
2) Antibody Response to Sp in Children Older than 5 Years (Group II)
Antibody responses to Sp in children aged >5 years are summarized in Table 8 and Fig. 3B . For each serotype, GMCs were calculated from individual Patients were vaccinated with PCV7 at months 0 and 2, and with PPSV23 at month 4. Blood was drawn for serological testing at months 0, 3, 5 and 13. B. In group II, antibodies were measured after one dose of PPSV23 at month 0 and blood was drawn for serological tests at months 0, 1, 3, and 13. GMC, geometric concentration; PCV7, pneumococcal conjugate vaccine 7-valent; PPSV23, pneumococcal polysaccharide vaccine 23-valent; Pre, prevaccination. Pre-existing antibody titers are known to decrease to low or unprotected levels after HCT in both allogeneic and autologous HCT recipients of blood and marrow grafts [20] [21] [22] [23] [24] . In our patients, pre- Earlier studies showed a poorer response to unconjugated PPSV23 and unconjugated Hib vaccine [25] [26] [27] and PPSV23 priming induced hyporesponsiveness to subsequent PCV7 28) . The immunologic response to PPSV23 is also known to be lower and delayed despite broader coverage 27, 29, 30) . For these reasons, . Patients in our study showed good immune responses after Hib and PCV7 vaccination. However, PPSV23 induced neither a sustained antibody response in group II (except for 9V), nor a boosting effect in group I. This observation was contrary to previous reports of the EBMT trial 31, 32) where a significant boosted immune response was observed with a vaccination schedule of three doses of PCV7 plus PPSV23. This difference could be due to variation between the schedules of our study and the EBMT trial (two doses of PCV plus PPSV23 vs.
three doses of PCV7 plus PPSV23), the low patient number in our study compared to the EBMT trial .
Therefore, the antibody observed in our study may be functional as well. These potential limitations will need to be examined further in Korean HCT recipients in future studies.
In conclusion, we performed a prospective study to measure antibody response after both Hib and Sp vaccination in Korean pediatric HCT recipients. We 
